CD38 and Miyoshi myopathy: For front‐line therapy, the availability of the novel drug class for MM, CD38‐targeting antibody (daratumumab), was approved for newly diagnosed MM patients in the United States (US) in 2018 and 2019 for patients who are ineligible and eligible for transplant, respectively.